CRDL stock surged +39% over the past 30 days, driven by positive Phase II ARCHER trial results publication and strong earnings beat. Over the past quarter, shares rose +34%, supported by Phase III MAVERIC trial enrollment milestones and $31 million in financing.

Teva Pharmaceutical Industries (TEVA), a global leader in generic and innovative medicines, does not pay a dividend. The company suspended dividends in December 2017 amid efforts to strengthen its balance sheet following high debt from past acquisitions. Prior to suspension, TEVA offered quarterly payments, with the last at $0.09 per share (ex-date November 27, 2017). Current dividend yield stands at 0%, and there is no forward dividend or scheduled ex-dividend date. This positions TEVA outside traditional dividend categories like high-yield or growth stocks, focusing instead on reinvestment for operational turnaround. From what I see, investors seeking immediate income should look elsewhere, but TEVA's robust cash generation signals potential for future policy shifts.

As Teva Pharmaceutical Industries (TEVA), a global leader in generic and innovative medicines, prepares to report first-quarter 2026 earnings on April 29, followed by a conference call at 8:00 a.m. ET, I'm paying close attention. This will be the first major update since full-year 2025 results, which delivered $17.3 billion in revenues, up 4% year-over-year, largely thanks to innovative products like AUSTEDO surpassing $2 billion annually. Investors like us will want to see clear progress on the "Pivot to Growth" strategy, especially as generics face headwinds, including a $1.1 billion impact from Revlimid in 2026. From what I see, shares have climbed significantly on prior beats—such as the +46% EPS surprise in Q4 2025—so this report could either reinforce momentum or highlight risks from pricing pressures and divestitures like the Japan operations.

I've been tracking TEVA, the stock of Teva Pharmaceutical Industries, as it builds a multi-year up-channel after reversing from a prolonged bottom. From what I see on the daily chart, the structure remains solidly bullish, with price having broken decisively above the 200-day moving average. Shorter-term, it holds an uptrend, positioned above most simple and exponential moving averages, such as the MA20 at $29.95 and MA50 at $29.52. A recent pullback has it testing dynamic support near the 20-day MA, which aligns with channel lows noted in trader analyses on platforms like TradingView. One thing that stands out is the declining volume during this consolidation, which often builds pressure for the next upward leg.

In recent trading, Teva Pharmaceutical Industries (TEVA) stock has held firm near the top of its 52-week range, drawing investor attention to its growing biosimilars portfolio. From what I see, the shares have gained from solid results in branded products such as AUSTEDO and AJOVY, along with key regulatory steps that highlight the company's shift to higher-margin innovative therapies. Macroeconomic pressures continue to weigh on generics, but Teva's emphasis on complex generics and biosimilars has kept the price steady, building confidence in its turnaround story through this market cycle.

ASRT stock surged +66% over the past 30 days, driven by strong Q4 2025 earnings beat and optimistic 2026 guidance highlighting Rolvedon growth. Over the past quarter, the stock rose +117%, fueled by improving gross margins, stable product demand, and analyst price target increases.

United Therapeutics Corporation focuses on biotechnology innovations for chronic and life-threatening conditions, particularly in pulmonary diseases. The company's portfolio centers on treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), featuring products like Tyvaso (treprostinil inhalation solution), Orenitram (oral treprostinil), Remodulin, and Adcirca.

Shares of United Therapeutics (UTHR) are surging approximately +17% in premarket trading on Monday, March 30, 2026, with the market not yet open. The primary catalyst is a landmark Phase 3 clinical trial announcement: the TETON-1 pivotal study of nebulized Tyvaso® (treprostinil) met its primary endpoint for treating idiopathic pulmonary fibrosis (IPF), exceeding the already impressive treatment effects seen in the previously completed TETON-2 study.

Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.

HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.

Regencell Bioscience Holdings (RGC) has emerged as one of the most electrifying stories in the stock market in 2025, captivating traders and investors with its staggering price movements.

Tilray Brands, Inc. (Nasdaq: TLRY) is a global leader in the cannabis, beverage, and wellness industries, headquartered in New York and Leamington, Ontario.

Artificial intelligence-powered trading robots have been making waves, demonstrating their capabilities in the volatile world of finance. At "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)," these AI-driven bots successfully generated a remarkable +strong performance while trading TLRY over the previous week. In this article, we delve into the technical analysis of TLRY's recent performance, focusing on key indicators, earnings results, market capitalization, and notable price and volume movements within the Pharmaceuticals: Other Industry.

Tickeron's quant team is thrilled to introduce the standout performer of the week, particularly noteworthy given the recent downturn in major stock indices. Despite the challenging market conditions, our quant team takes pride in highlighting the robot's exceptional achievement—delivering over 70% profitable signals for both long and short positions.

Installation Industry Stocks Surge with an Average 19.6% Monthly Gain

The past week has seen a remarkable surge in ophthalmology companies, with a collective performance increase of +33.31%. This surge has caught the attention of investors and analysts alike, particularly focusing on eight key stocks in this sector: HALO, ALIM, REGN, GKOS, ADVM, KALA, EYPT, and BHC. The positive outlook for this group is substantiated by the Volume Indicator and the Stock Fear & Greed Index.

At Tickeron, we recognize that seizing opportunities in an uptrend demands more than just market intuition. It requires unparalleled mathematical power and a meticulously tested trading algorithm – luxuries not easily accessible to the ordinary trader. That's why we're thrilled to introduce our best robot of the week:

In the world of biopharmaceutical companies specializing in surgeries and treatments for diseases like solid tumors, cancers, and hematologic malignancies, a select group of stocks has been making waves.

In these tumultuous times, where the S&P 500 has seen its fair share of turbulence for the third consecutive week, it's becoming increasingly clear that navigating the markets demands more than just intuition.

The Vascular sector has been making waves in the financial markets, with a remarkable surge of 27.39% in performance over the past week. This impressive performance has piqued the interest of investors and analysts alike. In this article, we will delve into this exciting theme and explore the group of tickers driving this growth. From positive momentum indicators to notable price movements and volume surges, we'll dissect the factors contributing to this sector's success.